News
10m
Capital Market on MSNBiocon edges higher after biologics arm launches autoimmune treatment drug Nepexto in AustraliaNepexto will be promoted by Generic Health, BBL's local partner and a leading provider of high-quality generic prescription, ...
Bengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced it ...
Etanercept is a TNF (tumor necrosis factor) inhibitor used to treat several autoimmune conditions, including rheumatoid ...
Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years ...
The shares of biopharmaceutical firm Biocon fell as much as 2.04 per cent in Tuesday's trading session, figuring among top ...
Shares of Biocon experienced a decline of 2.01% to Rs 386.70 in Tuesday's session, with the stock figuring among the top ...
Kirsty, Biocon's rapid-acting insulin, is the first FDA-approved interchangeable biosimilar to NovoLog in the US and will be ...
When Indian biotechnology firm Biocon and the world's biggest pharma company Pfizer announced their $350-million alliance in late October, the industry took it as another biotech pharma deal--by ...
Biocon aims to introduce generic versions of the obesity drug Wegovy in India and Canada by late 2026 or early 2027, ...
RSI, a key momentum indicator, shows that these 4 pharma stocks namely - Gland Pharma, Glenmark, Biocon and Laurus Labs are ...
Biocon and Viatris expect to close the transaction in the second half of this year. When it happens, Viatris will have one nominee on the Biocon board of directors.
2h
Capital Market on MSNBiocon Biologics launches biosimilar - Nepexto in AustraliaBiocon Biologics (BBL), a fully integrated global biosimilars company and subsidiary of Biocon, announced today it has launched Nepexto(R), a biosimilar to the reference ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results